Global Blood Therapeutics (NASDAQ:GBT) announced its earnings results on Thursday. The company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($1.03) by ($0.04), Briefing.com reports. During the same quarter last year, the firm posted ($0.83) EPS.
NASDAQ GBT traded down $0.17 during trading hours on Friday, reaching $47.00. 752,700 shares of the company traded hands, compared to its average volume of 765,230. The company has a current ratio of 16.79, a quick ratio of 16.79 and a debt-to-equity ratio of 0.03. Global Blood Therapeutics has a 12 month low of $30.15 and a 12 month high of $64.94. The company has a 50 day moving average of $49.25 and a two-hundred day moving average of $53.30. The stock has a market capitalization of $2.99 billion, a PE ratio of -13.78 and a beta of 1.57.
In other Global Blood Therapeutics news, insider De Dominicis Robert 490,012 shares of the stock in a transaction on Tuesday, October 22nd. Also, Director Deval L. Patrick sold 5,357 shares of the stock in a transaction dated Tuesday, October 8th. The stock was sold at an average price of $45.05, for a total transaction of $241,332.85. Following the completion of the sale, the director now directly owns 5,357 shares in the company, valued at approximately $241,332.85. The disclosure for this sale can be found here. In the last ninety days, insiders sold 14,698 shares of company stock worth $711,058. Corporate insiders own 4.30% of the company’s stock.
Several research analysts have recently weighed in on GBT shares. Wells Fargo & Co upped their target price on shares of Global Blood Therapeutics from $96.00 to $104.00 and gave the company an “outperform” rating in a research note on Wednesday, October 9th. Wedbush restated a “buy” rating and issued a $120.00 target price on shares of Global Blood Therapeutics in a research note on Wednesday, October 9th. BidaskClub downgraded shares of Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. JPMorgan Chase & Co. restated a “buy” rating on shares of Global Blood Therapeutics in a research note on Thursday, September 5th. Finally, Canaccord Genuity started coverage on shares of Global Blood Therapeutics in a research note on Wednesday. They issued a “hold” rating and a $50.00 target price for the company. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have assigned a buy rating to the stock. Global Blood Therapeutics has an average rating of “Buy” and a consensus price target of $88.08.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.